APA

Liu L., Yang L., Mi Y., Wang J., Li J., Zhang Y., Ma X., Qin T., Xu Z. & Xiao Z. (20110929). RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia. : Leukemia research.

Chicago

Liu Liang, Yang Lin, Mi Yingchang, Wang Jianxiang, Li Jianyong, Zhang Yue, Ma Xiaotang, Qin Tiejun, Xu Zefeng and Xiao Zhijian. 20110929. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia. : Leukemia research.

Harvard

Liu L., Yang L., Mi Y., Wang J., Li J., Zhang Y., Ma X., Qin T., Xu Z. and Xiao Z. (20110929). RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia. : Leukemia research.

MLA

Liu Liang, Yang Lin, Mi Yingchang, Wang Jianxiang, Li Jianyong, Zhang Yue, Ma Xiaotang, Qin Tiejun, Xu Zefeng and Xiao Zhijian. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia. : Leukemia research. 20110929.